CAH 10-Q Quarterly Reports

Cardinal Health Inc. reported strong performance for the second quarter of fiscal year 2026, driven by significant revenue growth and improved operating earnings. Total revenue increased by 19% year-over-year to $65.6 billion, fueled by robust sales in the Pharmaceutical and Specialty Solutions (Pharma) segment, primarily from branded and specialty pharmaceutical products and new customer acquisitions. The company also saw substantial growth in its Other segment, largely due to the acquisition of Advanced Diabetes Supply Group (ADS) and performance in OptiFreight® Logistics. Profitability also showed a marked improvement. GAAP operating earnings rose 29% to $707 million, while non-GAAP operating earnings saw a stronger 38% increase to $877 million. This growth was attributed to strategic acquisitions, including Solaris Health, and increased contributions from specialty pharmaceuticals and existing customers in the GMPD segment. Diluted EPS also followed this positive trend, with GAAP diluted EPS up 19% and non-GAAP diluted EPS up 36%. The company maintained adequate liquidity, although cash and equivalents decreased due to significant capital deployments for acquisitions and share repurchases.

Cardinal Health Inc. reported a strong first quarter of fiscal year 2026, with total revenue climbing 22% year-over-year to $64.0 billion. This growth was primarily driven by a significant increase in pharmaceutical and specialty solutions sales, fueled by both existing and new customers, alongside contributions from strategic acquisitions. Non-GAAP operating earnings saw a substantial 37% increase, reflecting improved profitability from recent MSO platform acquisitions and strong performance in branded and specialty pharmaceuticals. The company announced a significant move with the agreement to acquire Solaris Health for approximately $1.9 billion, a strategic expansion into the urology MSO space. While this acquisition will be financed through debt and cash, it underscores Cardinal Health's commitment to expanding its specialized healthcare services. Despite increased interest expenses related to new debt financing, the company's diluted EPS also showed healthy growth, with non-GAAP diluted EPS increasing by 36%.

Cardinal Health Inc. reported its third-quarter fiscal year 2025 results, demonstrating resilience despite revenue being flat year-over-year at $54.9 billion. This stability was achieved despite the prior-year impact of the OptumRx contract expiration, which was offset by growth in branded and specialty pharmaceutical sales. The company saw a significant increase in GAAP operating earnings, up 98% to $730 million, and a 21% increase in non-GAAP operating earnings to $807 million, driven by contributions from branded/specialty pharmaceuticals, cost savings initiatives, and MSO acquisitions. These improvements were partially tempered by the ongoing impact of the OptumRx contract expiration. Key strategic developments include substantial acquisitions in the healthcare services space, notably the $2.8 billion acquisition of GI Alliance (GIA) and the $1.1 billion acquisition of Advanced Diabetes Supply Group (ADSG), which are expected to bolster the Pharma and Other segments, respectively. While these acquisitions increase debt and acquisition-related costs, they signal a clear strategy to expand into higher-growth areas. The company's liquidity remains strong, supported by operating cash flow and credit facilities, though long-term debt has increased to fund these strategic investments. Investors should monitor the integration of these acquisitions and the continued impact of the OptumRx contract loss on future performance.

Cardinal Health Inc. (CAH) reported its second quarter fiscal year 2025 results, showing a decrease in revenue primarily due to the expiration of OptumRx contracts. Despite this revenue headwind, both GAAP and Non-GAAP operating earnings and diluted EPS saw significant year-over-year growth. This improvement was driven by enterprise-wide cost savings measures, growth in the BioPharma Solutions segment, and contributions from specialty networks and acquisitions. The company also highlighted substantial acquisitions, including ION and GI Alliance, which are expected to contribute to future growth, alongside a pending acquisition of Advanced Diabetes Supply Group. Management remains confident in the company's liquidity and ability to fund operations and future needs. Operationally, the Pharmaceutical and Specialty Solutions segment experienced a revenue decline but showed improved segment profit, driven by branded and specialty pharmaceutical products and BioPharma Solutions growth, partially offset by the OptumRx contract impact. The Global Medical Products and Distribution segment saw modest revenue and segment profit growth. The company also addressed significant cash outflows related to opioid litigation settlements, continuing its commitment to resolve these matters. Looking ahead, Cardinal Health is actively integrating recent acquisitions and expects them to positively impact future segment revenue and profit.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2025 results, demonstrating resilience and strategic execution despite the significant impact of the OptumRx contract expiration. While consolidated revenue saw a 4% decrease to $52.3 billion, primarily due to the OptumRx contract loss, the company achieved a 12% increase in non-GAAP operating earnings to $625 million, driven by strong performance in branded and specialty pharmaceuticals, including the favorable impact of early COVID-19 vaccine distribution. Operationally, the company navigated the loss of OptumRx revenue by focusing on growth from existing customers and cost-saving measures. The acquisition of Integrated Oncology Network (ION) for $1.1 billion was announced, signaling a strategic move to expand its oncology services. Despite a net cash used in operating activities of $1.6 billion, largely due to working capital unwinding from OptumRx and opioid settlement payments, Cardinal Health maintained a solid liquidity position and continued its capital deployment strategy through share repurchases and dividend payments.

Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2024, with total revenue increasing by 9% year-over-year to $54.9 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical and Specialty Solutions segment. While GAAP operating earnings saw a decline primarily due to litigation charges and goodwill impairment, the company's non-GAAP operating earnings showed significant improvement, increasing by 10% to $666 million. This highlights the company's operational performance excluding certain non-recurring or significant charges. Despite ongoing challenges, including significant litigation expenses and a goodwill impairment charge related to the GMPD segment, Cardinal Health demonstrated strong operational execution. The company's strategic acquisition of Specialty Networks for $1.2 billion aims to enhance its data analytics capabilities and expand its offerings in key therapeutic areas. However, investors should note the upcoming non-renewal of contracts with OptumRx, which represented 16% of fiscal year 2023 revenue, posing a significant headwind for fiscal year 2025. The company is actively managing its capital through share repurchases and dividends while maintaining adequate liquidity.

Cardinal Health Inc. (CAH) reported a strong second quarter for fiscal year 2024, with total revenue increasing by 12% year-over-year to $57.4 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical segment. The company also demonstrated significant improvements in profitability, with non-GAAP operating earnings up 20% and non-GAAP diluted EPS rising 38% year-over-year. This enhanced performance is attributed to stronger contributions from both the Pharmaceutical and Medical segments. Looking ahead, Cardinal Health announced a significant strategic move with the definitive agreement to acquire Specialty Networks for $1.2 billion in cash. This acquisition is expected to bolster the company's offerings in key therapeutic areas by enhancing analytics capabilities and accelerating data and research opportunities with biopharma manufacturers. The company also maintains a healthy liquidity position, with cash and equivalents increasing to $4.6 billion, supported by robust operating cash flow, and continues its capital return strategy through share repurchases and dividends.

Cardinal Health Inc. reported robust revenue growth in its first quarter of fiscal year 2024, with total revenue increasing by 10% to $54.8 billion, primarily driven by strong performance in its Pharmaceutical segment. This growth was fueled by increased branded and specialty pharmaceutical sales, as well as the early distribution of COVID-19 vaccines. The company also saw a significant improvement in Non-GAAP operating earnings, which rose 35% to $571 million, and Non-GAAP diluted EPS increased by 44% to $1.73, reflecting improved segment profitability and a lower share count due to repurchases. Despite overall positive operational trends, GAAP operating earnings showed a loss of $14 million due to a substantial $581 million goodwill impairment charge related to the Medical segment. While this impairment impacts GAAP figures, the company's Non-GAAP performance highlights underlying operational strength. Cardinal Health continues to manage its liquidity effectively, with $3.9 billion in cash and equivalents and a strong credit facility. The company is also actively returning capital to shareholders through dividends and share repurchases, with $3.8 billion remaining on its share repurchase authorization.

Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2023, with a 13% increase year-over-year, driven primarily by strong performance in its Pharmaceutical segment, particularly from branded and specialty pharmaceutical sales. The company also saw a significant improvement in GAAP operating earnings, shifting from a loss in the prior year to a gain, largely due to favorable litigation recoveries and the absence of prior-year goodwill impairment charges in the Medical segment. Non-GAAP operating earnings saw an 11% increase for the quarter, also bolstered by the Pharmaceutical segment. Despite the top-line growth and improved operating earnings, the Medical segment experienced a revenue decline due to lower volumes and pricing in personal protective equipment (PPE), though segment profit was positively impacted by lower PPE costs. The company continues to navigate inflationary pressures, which had a mixed impact across segments. Cardinal Health also actively managed its capital, repurchasing $1.5 billion in shares and paying $399 million in dividends during the nine-month period. The company maintains adequate liquidity and is managing its significant opioid litigation settlement obligations, with a substantial portion of the payments scheduled over the next 17 years.

Cardinal Health Inc. reported its second quarter fiscal year 2023 results, highlighting a 13% increase in revenue to $51.5 billion, driven primarily by branded and specialty pharmaceutical sales. While overall revenue showed strong growth, the company experienced a GAAP operating loss of $119 million. This loss was significantly influenced by a substantial goodwill impairment charge of $709 million related to its Medical segment. On a non-GAAP basis, which excludes these charges and other one-time items, the company reported operating earnings of $467 million and diluted EPS of $1.32, showing a slight increase of 4% year-over-year. The Pharmaceutical segment showed robust profit growth, while the Medical segment's profit declined due to lower volumes and inflationary pressures. The company's liquidity remains adequate, with $3.7 billion in cash and equivalents. Net cash provided by operating activities was $620 million for the six months ended December 31, 2022, though this was impacted by the second annual payment of $372 million for opioid lawsuit settlements. Cardinal Health also continued its capital deployment through share repurchases totaling $1.3 billion and dividend payments. The company faces ongoing challenges from inflation and supply chain costs, particularly impacting the Medical segment, and is implementing pricing strategies to mitigate these effects. Significant developments include the ongoing review initiated by the Shareholder Cooperation Agreement with Elliott.

Cardinal Health Inc. (CAH) reported its Q1 Fiscal Year 2023 results, with total revenue increasing by 13% to $49.6 billion, driven by strong performance in pharmaceutical distribution and specialty pharmaceutical customers. However, GAAP operating earnings saw a significant decline of 67% to $137 million, primarily impacted by a $154 million non-cash goodwill impairment charge in the Medical Segment and a general profit decrease in that segment due to inflationary pressures and lower Personal Protective Equipment (PPE) pricing and volumes. Non-GAAP operating earnings decreased by 20% to $423 million, also largely attributed to the challenges in the Medical segment. Despite these headwinds, the Pharmaceutical segment showed a 6% increase in profit. The company also made a $372 million annual payment related to the opioid litigation settlement and repurchased $1.0 billion of its common shares. Management believes the company has adequate capital resources to meet its obligations, but acknowledges potential impacts from inflationary pressures, supply chain disruptions, and ongoing litigation. Key financial takeaways include a substantial goodwill impairment, reduced operating earnings despite revenue growth, and continued investment in share buybacks. Investors should monitor the Medical segment's performance, the ongoing impact of inflation, and the resolution of significant legal matters, particularly the opioid litigation, which continues to represent a substantial financial commitment.

Cardinal Health Inc. reported a significant increase in revenue for the third quarter of fiscal year 2022, with a 14% rise to $44.8 billion, driven by strong performance in pharmaceutical distribution. However, the company experienced a GAAP operating loss of $97 million, primarily due to substantial goodwill impairment charges in the Medical segment totaling $474 million. This impairment was largely attributed to increased inflationary pressures and ongoing global supply chain constraints impacting the Medical segment. Despite the GAAP loss, non-GAAP operating earnings decreased by 21% to $545 million, also affected by the Medical segment's performance. The company made significant progress on its opioid litigation settlement, with the agreement becoming effective in April 2022, involving a commitment of up to $6.0 billion over 18 years. Cardinal Health also repurchased $1.0 billion of its common stock during the nine-month period, demonstrating a commitment to returning capital to shareholders.

Cardinal Health, Inc. reported its financial results for the second quarter of fiscal year 2022, ending December 31, 2021. The company experienced a revenue increase of 9% to $45.5 billion for the quarter, driven primarily by growth in pharmaceutical distribution and specialty pharmaceutical customers. However, the company reported a GAAP operating loss of $950 million for the quarter, largely due to a significant $1.3 billion pre-tax non-cash goodwill impairment charge related to its Medical segment. Despite the GAAP loss, non-GAAP operating earnings decreased by 26% to $467 million, reflecting challenges in the Medical segment stemming from increased inflationary pressures, global supply chain constraints, and the divestiture of the Cordis business. The Pharmaceutical segment showed modest growth in profit. Investors should note the ongoing opioid litigation settlement developments, which have a substantial financial impact, and the continued inflationary pressures impacting the Medical segment's profitability. The company maintains sufficient liquidity and is actively managing its capital resources and debt.

Cardinal Health reported a significant revenue increase of 13% to $44.0 billion for the first quarter of fiscal year 2022, driven primarily by strong performance in its pharmaceutical distribution and specialty pharmaceutical segments. Despite the revenue growth, non-GAAP operating earnings saw a decrease of 15% to $527 million, primarily due to increased supply chain costs, including commodities, transportation, and labor, within the Medical segment. The company also saw a shift from a GAAP operating loss in the prior year ($624 million) to GAAP operating earnings of $415 million, largely due to the absence of a substantial opioid litigation charge that impacted the prior year's results. The company has made progress on its proposed opioid litigation settlement, with a significant portion of its first annual payment placed into escrow. However, this settlement remains contingent on sufficient participation from states and political subdivisions. Cardinal Health also completed the divestiture of its Cordis business, which impacted Medical segment revenue and profit, and initiated an accelerated share repurchase program during the quarter. Management believes it has adequate capital resources to meet its obligations, including potential opioid settlement payments, though future acquisitions might necessitate additional financing.

Cardinal Health Inc. reported flat revenue of $39.3 billion for the third quarter of fiscal year 2021, mirroring the prior year's results which included an unusual surge in pharmaceutical sales due to early COVID-19 purchasing. For the nine-month period, revenue saw a 3% increase to $119.9 billion, driven by pharmaceutical distribution and specialty solutions, though partially offset by COVID-19 related volume declines. The company's non-GAAP operating earnings remained stable year-over-year for the nine months, but saw a slight decrease of 4% for the quarter. Significant litigation charges related to opioid lawsuits continue to impact GAAP earnings, although a substantial tax benefit from a net operating loss carryback provided a boost to the nine-month GAAP results. The company is progressing with the divestiture of its Cordis business, expected to close in the first quarter of fiscal 2022, and has sufficient liquidity to manage its operations and obligations.

Cardinal Health Inc. (CAH) reported its second quarter fiscal year 2021 results, demonstrating revenue growth driven by its Pharmaceutical segment. Total revenue increased by 5% year-over-year for both the three and six months ended December 31, 2020, reaching $41.5 billion and $80.6 billion, respectively. This growth was primarily attributed to higher sales from pharmaceutical distribution and specialty solutions customers. While revenue showed a positive trend, the company's GAAP operating earnings presented a mixed picture. For the three months ended December 31, 2020, GAAP operating earnings saw a significant increase of 38% to $461 million, largely due to a favorable comparison to prior year recall costs. However, for the six months ended December 31, 2020, the company reported a GAAP operating loss of $163 million, significantly improved from a $4.9 billion loss in the prior year period, primarily due to substantial charges related to opioid litigation in the prior year. Non-GAAP operating earnings, which exclude certain charges, showed more stable performance, increasing slightly for the six-month period while decreasing marginally for the three-month period.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2021 results, with total revenue reaching $39.1 billion, a 5% increase year-over-year, primarily driven by growth in pharmaceutical distribution and specialty pharmaceutical customers. While revenue showed a healthy increase, the company reported a GAAP operating loss of $624 million, significantly improved from the prior year's loss of $5.3 billion. This improvement is largely attributable to a substantial reduction in litigation charges related to opioid lawsuits, which decreased from $5.63 billion in the prior year to $1.02 billion in the current quarter. Excluding these significant litigation charges and other one-time items, the company's non-GAAP operating earnings rose by 7% to $618 million, and non-GAAP diluted EPS increased by 19% to $1.51. The company continues to navigate the ongoing opioid litigation, with negotiations for a global settlement framework in progress, and has accrued $6.59 billion for potential settlement payments. Operationally, the Pharmaceutical segment saw a 5% revenue increase, while the Medical segment experienced a 1% revenue increase. Both segments contributed positively to segment profit, with Medical segment profit showing a notable 36% increase due to cost savings. The company maintained a stable cash and equivalents balance of $2.7 billion, generating $270 million in operating cash flow during the quarter, which was used to fund dividends and capital expenditures. Cardinal Health appears to be managing its liquidity effectively and is focused on operational improvements, although the ongoing opioid litigation and the broader economic impact of COVID-19 remain key areas of watch.

Cardinal Health Inc. (CAH) reported its third-quarter fiscal year 2020 results, showing an 11% increase in revenue to $39.2 billion, driven by higher pharmaceutical distribution and specialty solutions sales, partly due to customer purchasing acceleration related to COVID-19. However, the company experienced below-average sales volume in March following this surge. The company also incurred a significant pre-tax charge of $5.63 billion related to the estimated liability for opioid lawsuits, which heavily impacted GAAP net earnings and EPS, resulting in a GAAP diluted loss per share of $(14.84) for the nine months ended March 31, 2020. Despite these challenges, non-GAAP operating earnings saw an 8% increase for the quarter and a 5% increase year-to-date, reflecting operational efficiencies and performance in key segments. Liquidity remains adequate, with $2.3 billion in cash and equivalents and strong operating cash flow generation. The company continues to manage its debt, with $888 million deployed for debt repayments during the nine-month period. While the COVID-19 pandemic introduces uncertainty, particularly regarding supply chain disruptions and potential impacts on sales volume, Cardinal Health believes it has sufficient resources to meet its obligations and fund future operations, including potential opioid settlement payments. Investors should closely monitor the ongoing opioid litigation developments and the company's ability to navigate the economic impacts of the pandemic.

Cardinal Health Inc. (CAH) reported its second quarter fiscal year 2020 results, highlighting a 5% increase in total revenue to $39.7 billion, driven primarily by growth in its pharmaceutical distribution and specialty solutions businesses. While revenue showed positive momentum, the company's GAAP operating earnings were significantly impacted by a $96 million charge related to a voluntary surgical gown recall and a substantial $5.63 billion pre-tax charge for the estimated liability associated with opioid litigation. Despite these significant charges, the company's non-GAAP operating earnings saw a modest 1% increase for the quarter and a 4% increase for the six-month period, reflecting underlying operational performance that excludes these extraordinary items. Investors should note the company's proactive approach to managing its balance sheet, including debt repayments and share repurchases, alongside maintaining a strong cash position. The opioid litigation settlement framework, while substantial, provides a path toward resolution, though uncertainties remain regarding final terms and future liabilities related to treatment medications and program changes. The surgical gown recall, while impacting current quarter results, is not expected to materially impact the long-term goodwill of the Medical Unit at this time. The company reiterated its belief in having adequate capital resources to meet its obligations, including potential opioid settlement payments.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2020 results, marked by a significant GAAP operating loss of $5.3 billion. This loss was primarily driven by a substantial $5.63 billion pre-tax charge related to an estimated liability for opioid lawsuits and claims. Despite this GAAP loss, the company reported a 6% increase in non-GAAP operating earnings to $577 million, driven by cost-saving measures and growth in its distribution and services businesses. Revenue saw a 6% increase to $37.3 billion, largely due to strong performance in pharmaceutical distribution and specialty pharmaceutical customers. Key financial highlights include a decrease in cash and equivalents from $2.5 billion to $1.2 billion, attributed to operational cash usage and significant share repurchases. The company also announced an agreement in principle for a global settlement framework to resolve opioid lawsuits with states and political subdivisions, involving a cash component of up to $5.56 billion over eighteen years. While the GAAP results were heavily impacted by the opioid litigation accrual, the underlying operational performance, as reflected in non-GAAP metrics, showed resilience and growth.

Cardinal Health, Inc. reported its third-quarter fiscal year 2019 results, showcasing revenue growth driven by its pharmaceutical distribution and specialty pharmaceutical customers. Total revenue increased by 5% to $35.2 billion for the quarter and by 7% to $108.2 billion for the nine months ended March 31, 2019. Despite revenue growth, GAAP operating earnings saw a decline of 21% for the quarter, primarily due to decreased segment profit in Pharmaceutical and Medical segments and increased restructuring costs. However, for the nine-month period, GAAP operating earnings surged by 45%, largely boosted by a significant gain from the divestiture of the naviHealth business. The company's liquidity remains strong, with cash and equivalents increasing to $3.4 billion at the end of the quarter. This increase was supported by operating activities and proceeds from the naviHealth sale, partially offset by share repurchases and dividend payments. Looking ahead, the company plans to use its cash on hand to repay a $1.0 billion note maturing in June 2019. Overall, the report indicates a mixed financial performance with solid revenue top-line growth and improved cash position, but facing pressures on profitability due to segment-specific challenges and restructuring expenses.

Cardinal Health Inc. reported its second-quarter fiscal year 2019 results, demonstrating revenue growth driven by its pharmaceutical distribution and specialty pharmaceutical businesses. While overall revenue saw a positive uptick of 7% year-over-year, the company's profitability faced headwinds, particularly a decline in non-GAAP operating earnings and diluted EPS. This was attributed to challenges in the pharmaceutical segment's generics program, increased costs for Cardinal Health Brand products, and adverse pharmaceutical customer contract renewals. The company also recognized a significant gain from the divestiture of its naviHealth business, which bolstered GAAP earnings. Despite these profitability pressures, Cardinal Health maintained a strong liquidity position, with an increase in cash and equivalents and ample credit facilities, alongside continued capital deployment through dividends and share repurchases.

Cardinal Health's Q1 Fiscal Year 2019 report for the period ending September 29, 2018, shows a significant increase in GAAP operating earnings driven by the divestiture of its naviHealth business, which contributed a $508 million gain. However, non-GAAP operating earnings saw a 11% decrease due to challenges in the Pharmaceutical segment, including generics program performance and customer contract renewals, alongside increased costs for Cardinal Health Brand products. Revenue grew 8% to $35.2 billion, primarily from pharmaceutical distribution, though partially impacted by the prior divestiture of its China distribution business. Despite the operational headwinds in certain segments, the company demonstrated solid cash flow generation, with cash and equivalents increasing to $2.0 billion. This was bolstered by the naviHealth sale proceeds and operating activities, partially offset by significant share repurchases and dividend payments. The company's liquidity position remains strong, supported by its credit facilities. Investors should note the impact of the U.S. Tax Cuts and Jobs Act, which positively affected earnings per share, and be aware of ongoing litigation, particularly concerning opioid distribution, and potential future goodwill impairments in the Medical segment.

Cardinal Health Inc. reported its third-quarter fiscal year 2018 results, showcasing a 6% increase in revenue to $33.6 billion, driven by growth in pharmaceutical distribution and specialty pharmaceutical customers, as well as the contribution from the recent Patient Recovery Business acquisition. However, GAAP operating earnings saw a 10% decrease to $546 million, impacted by increased amortization, litigation charges related to IVC filters, and performance in specific product lines. Non-GAAP operating earnings showed a modest 3% increase to $781 million, highlighting the company's focus on underlying operational performance. The company also reported a significant impact from the Tax Cuts and Jobs Act, which resulted in a substantial provisional net tax benefit. The balance sheet reflects a notable decrease in cash and equivalents from $6.9 billion to $2.2 billion, primarily due to $6.1 billion spent on acquisitions, alongside dividend payments and share repurchases. The company successfully divested its China distribution business, generating net proceeds of $861 million. Looking ahead, Cardinal Health anticipates continued operating cost and inventory challenges in its Medical segment's Cordis business and expects customer pricing changes to negatively impact its Pharmaceutical segment's profit in the near future.

Cardinal Health, Inc. reported its second quarter fiscal year 2018 results, ending December 31, 2017. The company saw a revenue increase of 6% to $35.2 billion for the quarter and 4% to $67.8 billion for the first six months, driven primarily by growth in pharmaceutical distribution and medical segment acquisitions. Despite revenue growth, GAAP operating earnings saw a significant decline of 26% for the quarter and 39% for the six months. This was largely due to increased acquisition-related costs, litigation charges (specifically for IVC filter product liability claims), and costs associated with IT system replacements. Non-GAAP operating earnings showed more resilience, increasing by 4% for the quarter but declining slightly by 2% for the six-month period, reflecting adjustments for these one-time or non-operational items. A significant factor impacting net earnings and EPS was the provisional benefit from the U.S. Tax Cuts and Jobs Act, which lowered corporate tax rates and resulted in a substantial one-time tax benefit. Cash flow from operations remained positive, but the company's cash balance decreased significantly due to the $6.1 billion acquisition of the Patient Recovery Business. Cardinal Health also completed the divestiture of its China distribution business in February 2018. Investors should note the ongoing litigation related to opioid distribution and IVC filters, which represents a material contingent liability.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2018 results, showcasing a 2% increase in total revenue to $32.6 billion, primarily driven by growth in specialty and pharmaceutical distribution customers, and contributions from Medical segment acquisitions. However, GAAP operating earnings saw a significant 51% decrease to $262 million, largely due to restructuring costs associated with the Medical segment's surgeon glove distribution, increased amortization from the recent Patient Recovery Business acquisition, and litigation charges. Non-GAAP operating earnings also declined by 9% to $610 million, reflecting some of these headwinds. The company completed a major acquisition of Medtronic's Patient Recovery Business for $6.1 billion in July 2017. This significantly impacted cash flow, with cash and equivalents dropping from $6.9 billion to $1.2 billion due to acquisition funding, debt redemption, and share repurchases, alongside operating cash flow generation. Despite the operational challenges impacting near-term profitability, management believes it has adequate capital resources for its ongoing needs, but may require additional financing for future acquisitions.

Cardinal Health, Inc. (CAH) reported its Q3 fiscal year 2017 results, showcasing a 4% increase in revenue to $31.8 billion for the quarter, driven by growth in its specialty pharmaceutical and pharmaceutical distribution sectors. While revenue saw a positive trend, operating earnings and diluted EPS experienced a slight decline compared to the prior year period, primarily attributed to generic pharmaceutical customer pricing changes and the loss of a significant distribution customer. Despite these pressures, the company is strategically expanding its Medical segment with a significant pending acquisition of Medtronic's Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion, which is expected to be funded through a combination of debt, existing cash, and operating cash flows. The company's financial health remains stable, with a cash balance of $1.4 billion at the end of the quarter. Shareholder returns are being maintained through dividends and a share repurchase program. Management's outlook indicates potential continued pressure on Pharmaceutical segment profit in fiscal 2018 due to ongoing pricing changes, but the company remains focused on strategic growth initiatives and operational efficiencies. Investors should monitor the integration of the Medtronic acquisition and the impact of pharmaceutical pricing dynamics on future profitability.

Cardinal Health Inc. reported its second quarter fiscal year 2017 results, with total revenue increasing by 5% to $33.1 billion for the quarter and 10% to $65.2 billion for the six months ended December 31, 2016. This growth was primarily driven by the Pharmaceutical segment's sales to pharmaceutical distribution customers and the Medical segment, which benefited from the inclusion of the Cordis business acquired in October 2015. However, operating earnings saw a decline, with GAAP operating earnings down 4% to $542 million for the quarter and 9% to $1,076 million for the six months. Non-GAAP operating earnings also decreased by 4% and 6%, respectively. These declines are attributed to pricing changes in the generic pharmaceutical market, the loss of a major pharmaceutical distribution customer, and reduced branded pharmaceutical inflation. Despite these pressures, the company continues to return capital to shareholders through dividends and share repurchases, and it maintains adequate capital resources for its operational needs.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2017 results, ending September 30, 2016. The company saw a significant 14% increase in total revenue, reaching $32.0 billion, primarily driven by growth in its Pharmaceutical segment from new and existing customers. However, both GAAP and non-GAAP operating earnings and diluted EPS experienced a decline compared to the prior year. This decrease was attributed to factors such as generic pharmaceutical customer pricing changes, reduced branded pharmaceutical inflation, and the loss of a significant pharmaceutical distribution customer. Despite the decline in profitability metrics, the company's Medical segment showed a strong 26% increase in profit, bolstered by acquisitions, including the notable Cordis acquisition in the prior year, and contributions from its own branded products. The company also provided an updated outlook, now expecting fiscal 2017 Pharmaceutical segment profit to be less than fiscal 2016 profit, reflecting the ongoing challenges in the pharmaceutical distribution landscape. Investors should monitor the impact of pharmaceutical pricing changes and customer dynamics on future earnings.

Cardinal Health Inc. reported strong revenue growth of 21% and 20% for the three and nine months ended March 31, 2016, respectively, driven primarily by its Pharmaceutical segment and strategic acquisitions. The company demonstrated significant increases in both GAAP (11% and 15%) and non-GAAP (20% and 21%) operating earnings for the respective periods, signaling effective operational execution and integration of acquired businesses. Diluted EPS also saw substantial year-over-year growth, with non-GAAP diluted EPS reaching $1.43 for the quarter and $4.10 for the nine-month period, reflecting improved profitability. However, the company's cash and equivalents decreased due to significant investments in acquisitions ($3.4 billion), dividends, and share repurchases, indicating a strategic deployment of capital for growth and shareholder returns. The company highlighted the successful completion of three major acquisitions during the nine-month period: Cordis (medical devices), naviHealth (post-acute care management), and Harvard Drug (generic pharmaceuticals). These acquisitions are expected to expand its Medical and Pharmaceutical segments' portfolios and geographic reach. Despite substantial capital deployment, Cardinal Health maintains adequate liquidity through its existing credit facilities and operating cash flow, and remains compliant with its financial covenants, suggesting a stable financial position to support ongoing operations and future growth initiatives.

Cardinal Health Inc. (CAH) reported solid revenue growth driven by acquisitions and existing pharmaceutical distribution customers for the second quarter of fiscal year 2016. The company completed three significant acquisitions: Cordis, naviHealth, and Harvard Drug, totaling over $3.2 billion, which are expected to expand its Medical and Pharmaceutical segments. While revenue increased by 23% year-over-year, the company saw growth in both GAAP and non-GAAP operating earnings, with non-GAAP operating earnings increasing by 14% for the quarter. Diluted EPS also saw an increase, with GAAP diluted EPS up 14% and non-GAAP diluted EPS up 8% compared to the prior year. Despite the positive revenue and earnings growth, the company experienced a decrease in its cash and equivalents balance due to significant deployment for acquisitions and dividend payments. However, Cardinal Health maintains adequate capital resources and is in compliance with its financial covenants. Investors should note the impact of acquisition-related costs, particularly amortization, on GAAP earnings and the company's continued strategy of growth through strategic acquisitions.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2016 results, showcasing strong revenue growth driven by its Pharmaceutical segment. The company's total revenue increased by 17% year-over-year to $28.1 billion, primarily due to increased sales from existing and new pharmaceutical distribution customers. GAAP operating earnings saw a significant 33% rise to $620 million, with GAAP diluted EPS up 47% to $1.15. This performance was bolstered by strategic acquisitions, including Harvard Drug and naviHealth, which closed during the quarter, and the subsequent acquisition of Cordis shortly after the period end, aimed at expanding the company's offerings in the pharmaceutical and medical segments. While the overall financial picture is positive with robust revenue and earnings growth, investors should note the impact of recent and pending acquisitions on expenses, particularly amortization and acquisition-related costs. The company's cash position decreased due to significant acquisition spending, but it maintained adequate liquidity through its credit facilities. The Medical segment experienced a slight profit decline, partly due to specific prior-year benefits in its Canada operations. Cardinal Health continues to focus on integrating new businesses and managing costs while pursuing strategic growth opportunities.

Cardinal Health, Inc. (CAH) reported a solid third quarter for fiscal year 2015, demonstrating revenue growth driven by both its Pharmaceutical and Medical segments. Total revenue increased by 18% year-over-year to $25.4 billion, with the Pharmaceutical segment showing particularly strong performance due to increased sales from existing and new distribution customers, including growth from the Red Oak Sourcing venture. The company also announced a significant strategic move with the pending acquisition of Johnson & Johnson's Cordis business for $1.9 billion, which is expected to enhance the Medical segment's product portfolio. Despite revenue growth, investors should note the ongoing impact of the Walgreens contract expiration on the nine-month revenue figures, though this was partially offset by strategic initiatives. The company's financial health remains robust, with an increase in operating earnings and a healthy cash position. Management expressed confidence in the company's ability to fund its operations and strategic initiatives, including the Cordis acquisition, through existing capital resources and projected cash flow. Shareholder returns were supported by continued dividend payments and significant share repurchases during the period.

Cardinal Health, Inc. (CAH) reported its third-quarter 2015 financial results for the period ending December 31, 2014. The company demonstrated revenue growth, driven primarily by its Pharmaceutical segment, with a notable increase in revenue for both the three-month and six-month periods compared to the prior year. This growth was attributed to new and existing distribution customers. Gross margin also saw an increase, reflecting this revenue expansion and strong performance in generic programs, though partially offset by customer pricing changes and the impact of new hepatitis C drugs. While operating earnings showed a modest increase, the company experienced a significant loss on the extinguishment of debt during the quarter due to debt refinancing activities. Earnings from continuing operations for the six-month period declined year-over-year, impacted by the debt extinguishment and prior-year tax benefits. The company maintained a strong liquidity position with a substantial cash and equivalents balance and active share repurchase programs, alongside continued debt management and refinancing efforts.

Cardinal Health Inc. reported its third-quarter results for the period ending September 29, 2014. Revenue for the quarter saw a slight decrease of 2% to $24.1 billion, primarily due to the expiration of a significant pharmaceutical distribution contract with Walgreen Co. in the prior year. Despite the revenue dip, gross margin improved by 6% to $1.3 billion, driven by growth from other customers and strong performance in generic programs. Operating earnings declined by 1% to $466 million, largely impacted by litigation charges, particularly related to a U.S. Drug Enforcement Administration investigation for which the company accrued $27 million. Net earnings from continuing operations decreased by 22% to $266 million, mainly due to a favorable tax settlement in the prior year that did not recur. The company demonstrated a commitment to shareholder returns by repurchasing $360 million in common stock and paying $119 million in dividends during the quarter. Overall, while facing headwinds from contract expirations and legal matters, the company's core operations showed resilience with improved gross margins.

Cardinal Health Inc.'s (CAH) third-quarter fiscal year 2014 results show a notable revenue decline primarily due to the expiration of the Walgreens distribution contract. Despite this significant headwind, the company demonstrated resilience with flat gross margins for the quarter and a slight increase for the nine-month period, bolstered by acquisitions and strong generic program performance. Operating earnings saw an increase, demonstrating effective cost management and strategic execution in the face of revenue challenges. While the company is navigating the impact of the lost Walgreens contract, it is actively positioning for future growth through strategic initiatives like the CVS joint venture for generic sourcing and the announced acquisition of Access Closure. The balance sheet remains strong, with a significant increase in cash and equivalents, providing flexibility for continued capital deployment through dividends and share repurchases, signaling management's confidence in the company's ongoing operational performance and strategic direction.

Cardinal Health, Inc. reported its fiscal second quarter and first half results for the period ending December 31, 2013. The company experienced a significant revenue decline of 12% for the quarter and 9% for the six-month period, primarily driven by the expiration of its pharmaceutical distribution contract with Walgreens. Despite the revenue drop, gross margin saw a 10% increase for the quarter and 9% for the six months, attributed to acquisitions, margin rate expansion, and new customer wins. Operating earnings showed modest growth of 2% and 3% for the respective periods, bolstered by the Medical segment's performance and improved margins in the Pharmaceutical segment, though offset by increased SG&A expenses and amortization. Net earnings from continuing operations declined 9% for the quarter but increased 7% for the six months, impacted by significant discrete tax items. The company's liquidity remains strong, with cash and equivalents increasing substantially due to improved operating cash flow and working capital management following the Walgreens contract expiration. A key strategic development during the quarter was the announcement of a generic sourcing joint venture with CVS Caremark, aimed at enhancing generic pharmaceutical sourcing.

Cardinal Health Inc. reported financial results for the three months ended September 30, 2013, showcasing a 5% decrease in total revenue to $24.5 billion, primarily driven by the expiration of key pharmaceutical distribution contracts with Walgreens and Express Scripts. Despite the revenue decline, the company demonstrated resilience with a 9% increase in gross margin to $1.3 billion and a 3% rise in operating earnings to $471 million. This performance was bolstered by strong generic pharmaceutical programs and the impact of recent acquisitions, alongside a significant positive impact from the settlement of federal and state tax controversies which boosted earnings from continuing operations by 25% to $340 million. The company's balance sheet shows a strengthened cash position, with cash and equivalents increasing to $2.8 billion from $1.9 billion at the prior quarter's end. This increase was largely attributable to improved operating cash flow, driven by working capital adjustments related to the aforementioned contract expirations. Management indicated confidence in current capital resources to fund ongoing operations, expenditures, and shareholder returns, while also acknowledging the potential need for additional capital for significant future acquisitions.

Cardinal Health Inc. (CAH) reported its fiscal third quarter results ending March 31, 2013. The company experienced a notable 9% decrease in revenue for the quarter and a 6% decrease for the nine-month period, primarily driven by the expiration of a significant pharmaceutical distribution contract with Express Scripts and ongoing brand-to-generic pharmaceutical conversions. Despite the revenue decline, gross margin saw a healthy increase of 7% for the quarter and 8% for the nine months, attributed to strong performance in the company's generic pharmaceutical programs. Financially, the company completed a significant acquisition of AssuraMed for $2.07 billion, funded by new debt issuance and existing cash. This acquisition is expected to expand their reach in serving patients at home and contribute positively to future earnings, excluding amortization of related intangibles. Cardinal Health also announced the non-renewal of its contract with Walgreens, a major customer, which is expected to have a net after-tax benefit to cash flow in fiscal 2014. Conversely, the renewal of contracts with CVS Caremark provides a stable revenue stream. The company maintained a strong liquidity position with a substantial cash balance and access to credit facilities.

Cardinal Health Inc. reported a net earnings of $303 million for the three months ended December 31, 2012, an increase from $262 million in the prior year period. Revenue for the quarter was $25.2 billion, a decrease of 7% compared to the prior year, primarily due to the expiration of a significant pharmaceutical distribution contract with Express Scripts and the impact of brand-to-generic pharmaceutical conversions. Despite the revenue decline, gross margin improved by 10% to $1.2 billion, driven by strong performance in generic pharmaceutical programs and favorable product mix in the Medical segment. Operating earnings also saw a healthy increase of 13% to $506 million. The company continued its focus on capital allocation, with $200 million in share repurchases and $165 million in dividends paid during the six-month period. Management reiterated confidence in the company's liquidity and ability to fund working capital, capital expenditures, and debt service requirements. However, the company faces ongoing litigation and investigations, including a significant proposed tax adjustment from the IRS related to transfer pricing, which is being contested. Additionally, the company announced a restructuring plan within its Medical segment, expected to incur approximately $79 million in pre-tax costs.

Cardinal Health Inc. reported a 3% decrease in revenue for the three months ended September 30, 2012, totaling $25.9 billion, primarily due to brand-to-generic pharmaceutical conversions. Despite the revenue dip, gross margin saw a healthy 7% increase to $1.2 billion, and operating earnings rose 11% to $457 million. This improvement was driven by strong performance in the Pharmaceutical segment's generic programs and a $22 million income from antitrust litigation settlements. Net earnings from continuing operations increased by 15% to $272 million, with diluted EPS at $0.79. The company's liquidity remains strong, with cash and equivalents increasing to $2.4 billion, supported by robust operating cash flow. Looking ahead, management anticipates continued revenue decrease in fiscal 2013 within the Pharmaceutical segment due to ongoing generic conversions and the expiration of a major distribution contract with Express Scripts. The company continues to focus on balanced capital deployment, including dividends and share repurchases, demonstrating a commitment to shareholder value despite revenue headwinds in specific segments. The company is also actively managing legal and tax contingencies, including ongoing IRS audits.

Cardinal Health Inc. reported strong performance for the third quarter and first nine months of fiscal year 2012, with total revenue increasing by 3% and 6% respectively compared to the prior year periods. This growth was driven by increased sales from existing customers and the impact of recent acquisitions. The company saw a significant improvement in operating earnings, up 18% and 20% for the respective periods, boosted by strong generic pharmaceutical programs and a favorable adjustment to contingent consideration related to the P4 Healthcare acquisition. Net earnings from continuing operations also showed positive trends, increasing by 33% for the quarter and 10% for the nine-month period. The company's balance sheet strengthened with an increase in cash and equivalents to $2.4 billion, supported by robust operating cash flow. Management expressed confidence in the company's liquidity to fund operations, capital expenditures, and shareholder returns, including dividends and share repurchases.

Cardinal Health Inc. reported solid revenue growth for the quarter and six months ended December 31, 2011, with a 7% increase in revenue for the quarter ($27.1 billion) and an 8% increase for the six-month period ($53.9 billion) compared to the prior year. This growth was driven by contributions from acquisitions and increased sales to existing customers across both its Pharmaceutical and Medical segments. The company also demonstrated significant improvement in operating earnings, which rose 31% and 22% for the respective periods, largely due to the strong performance of generic programs and acquisitions within the Pharmaceutical segment. Despite increased revenue, the company's net earnings saw a slight decrease for the six-month period ($498.8 million compared to $510.2 million), primarily due to a one-time gain from the sale of its investment in CareFusion in the prior year's comparable period. However, earnings from continuing operations remained robust, showing an increase for the quarter. The company maintained a strong liquidity position with $1.8 billion in cash and equivalents at the end of the period, supported by operating cash flow, and continued its commitment to shareholder returns through dividends and share repurchases.

Cardinal Health, Inc. reported its fiscal first quarter 2012 results for the period ending September 30, 2011. The company saw a 10% increase in consolidated revenue, reaching $26.8 billion, driven by contributions from recent acquisitions and growth from existing customers. This revenue growth translated into a 13% increase in gross margin to $1.1 billion and a 13% rise in operating earnings to $412 million. However, earnings from continuing operations declined by 19% to $237 million, primarily due to a significant gain on the sale of its investment in CareFusion in the prior year's comparable quarter. The company's balance sheet showed a healthy increase in cash and equivalents to $2.0 billion, supported by strong operating cash flow, despite substantial share repurchases and dividend payments. The Pharmaceutical segment demonstrated robust performance, with acquisitions and strong generic programs being key drivers of its profit growth. The Medical segment experienced a slight profit decrease due to increased commodity costs and a specific product import issue, though overall segment revenue grew. Cardinal Health remains focused on strategic growth through acquisitions while also returning value to shareholders via dividends and share repurchases. The company is managing its working capital effectively, as indicated by its days sales outstanding, inventory days, and days payable outstanding metrics. Despite some headwinds in the Medical segment and ongoing tax audits, the company maintains confidence in its liquidity and ability to fund its operations and growth initiatives.

Cardinal Health, Inc. (CAH) reported solid revenue growth for the third quarter of fiscal year 2011, with consolidated revenue increasing by 7% year-over-year to $26.1 billion. This growth was primarily driven by the Pharmaceutical segment, which saw a 7% increase in revenue, bolstered by recent acquisitions and strong generic program performance. The Medical segment also experienced revenue growth of 5%. Net earnings from continuing operations showed a significant increase of 11% to $249.5 million, or $0.71 per diluted share, reflecting improved profitability and operational execution. The company has been active in strategic acquisitions, including Kinray, Yong Yu, and P4 Healthcare, which contributed to revenue and segment profit growth in the Pharmaceutical segment. Despite increased costs in the Medical segment due to rising commodity prices, overall operating earnings saw a healthy increase of 22%. The company also continues to return capital to shareholders through dividends, with a recent increase in the quarterly dividend approved.

Cardinal Health, Inc. (CAH) reported its financial results for the quarter ended December 31, 2010. The company experienced revenue growth, driven primarily by its Pharmaceutical segment, which saw increased profit due to new generic launches and improved sourcing programs. However, the Medical segment faced headwinds, with flat profit for the quarter and a decline year-to-date, attributed to rising commodity costs and a strong prior-year flu season. Significant strategic initiatives were undertaken during the period, including substantial acquisitions in the pharmaceutical distribution space in both the US (Kinray) and China (Yong Yu), along with the acquisition of P4 Healthcare to bolster specialty pharmaceutical services. These acquisitions are expected to contribute positively to earnings in the latter half of fiscal 2011. The company also continued to divest its remaining stake in CareFusion, generating a gain and strengthening its balance sheet.

Cardinal Health Inc. reported a significant turnaround in its financial performance for the quarter ended September 30, 2010, compared to the same period in the prior year. The company achieved earnings from continuing operations of $294.4 million, a substantial improvement from a loss of $61.8 million in the prior year quarter. This positive shift was driven by a strong increase in gross margin, up 6% to $962.2 million, and a 52% surge in operating earnings to $363.9 million. Key factors contributing to this performance include the success of generic pharmaceutical programs and increased branded margins within the Pharmaceutical segment, as well as favorable comparisons due to the absence of significant restructuring and asset impairment charges recorded in the prior year. Operationally, total revenue saw a slight decrease of 1% to $24.4 billion, primarily due to customer losses and the impact of branded-to-generic pharmaceutical conversions in the Pharmaceutical segment, and the prior year's recognition of deferred intercompany revenue with CareFusion in the Medical segment. The company also completed the acquisition of P4 Healthcare for $509.1 million, expanding its presence in specialty pharmaceutical services. Furthermore, Cardinal Health finalized the sale of its remaining investment in CareFusion, realizing a $74.8 million gain. The company's liquidity remains robust, with cash and equivalents at $2.7 billion, supported by operating cash flow and the proceeds from the CareFusion investment sale, despite significant cash outflows for acquisitions and share repurchases.

Cardinal Health, Inc. reported solid revenue growth for the nine months ending March 31, 2010, with total revenue reaching $74.0 billion, a 3% increase year-over-year. This growth was primarily driven by the Pharmaceutical segment, which saw an increase in pharmaceutical price appreciation and volume. While revenue showed an upward trend, operating earnings experienced a slight decline of 1% to $973 million for the same period. This decrease was mainly attributed to higher distribution, selling, general, and administrative (SG&A) expenses, as well as increased restructuring and impairment charges. The company successfully navigated the complexities of the CareFusion spin-off, which significantly impacted year-over-year comparisons. The spin-off resulted in a substantial increase in cash and cash equivalents to $2.6 billion, bolstered by proceeds from the sale of CareFusion stock and strong operating cash flows. Despite ongoing litigation and tax matters, Cardinal Health maintained compliance with its financial covenants, indicating a stable liquidity position.

Cardinal Health, Inc. reported its financial results for the quarter ended December 31, 2009. The company saw a modest increase in revenue, up 3% year-over-year to $24.9 billion for the quarter. Operating earnings showed a more significant improvement, rising 17% to $366.8 million, driven by increased gross margins and a favorable litigation credit. A key event impacting the period was the spin-off of CareFusion Corporation on August 31, 2009. While this significantly reduced earnings from discontinued operations, the company is strategically managing its retained stake in CareFusion, having sold some shares and realizing a gain. Management is focused on core operations, with both the Pharmaceutical and Medical segments contributing to revenue growth, though segment profit dynamics varied. The company also actively managed its debt, including a significant debt tender, and continued its share repurchase program.

Cardinal Health, Inc. (CAH) reported its financial results for the quarter ended September 30, 2009, marking a period of significant strategic transition with the spin-off of CareFusion Corporation. Revenue for the quarter saw a modest increase of 6% year-over-year, reaching $24.8 billion. However, operating earnings declined by 16% to $240 million, impacted by increased restructuring costs related to the CareFusion spin-off and a significant impairment charge of $23 million for SpecialtyScripts. The company experienced a net loss of $38.2 million for the quarter, a sharp contrast to the prior year's net earnings of $249.1 million. This downturn was heavily influenced by a $172 million tax charge related to the anticipated repatriation of foreign earnings and a $40 million loss on the extinguishment of debt. Despite these challenges, operational cash flow remained positive at $406 million, driven by working capital management. The balance sheet reflects a substantial decrease in assets and liabilities, largely due to the reclassification of CareFusion as discontinued operations. Investors should note the strategic shift following the CareFusion spin-off, which has reshaped the company's operational and financial profile. While revenue growth is positive, profitability is under pressure from one-time charges and ongoing restructuring. The company's liquidity remains adequate, supported by cash reserves and credit facilities. Management is focused on cost control initiatives and navigating the complex healthcare regulatory environment.